AR060268A1 - Tiazolil - dihidro - indazoles - Google Patents

Tiazolil - dihidro - indazoles

Info

Publication number
AR060268A1
AR060268A1 ARP070101386A ARP070101386A AR060268A1 AR 060268 A1 AR060268 A1 AR 060268A1 AR P070101386 A ARP070101386 A AR P070101386A AR P070101386 A ARP070101386 A AR P070101386A AR 060268 A1 AR060268 A1 AR 060268A1
Authority
AR
Argentina
Prior art keywords
alkyl
cycloalkyl
aryl
optionally substituted
group
Prior art date
Application number
ARP070101386A
Other languages
English (en)
Inventor
Ingo Pragst
Anne T Joergensen
Alexander Pautsch
Klaus Erb
Steffen Breitfelder
Stefan Scheuerer
Michael Pieper
Udo Maier
Matthias Grauert
Torsten Hoffmann
Christoph Hoenke
Trixi Brandl
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR060268A1 publication Critical patent/AR060268A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Sus tautomeros, racematos, enantiomeros, diastereomeros y sus mezclas, así como eventualmente sus sales por adicion de ácidos, solvatos e hidratos farmacologicamente inocuos, así como procedimientos para la preparacion de estos tiazolil-dihidro- indazoles y su uso como medicamentos. Reivindicacion 1: Los compuestos de la formula general (1), en los que Ra hidrogeno o un radical eventualmente sustituido seleccionado del grupo compuesto por alquilo C1-8, alquenilo C2-8, alquinilo C2-8, cicloalquilo C3-8, cicloalquenilo C3-8, haloalquilo C1-6, arilo C6-14, aril C6-14-aIquilo C1-5, heteroarilo C5-10, cicloalquil C5-10-alquilo C1-4, cicloalquenil C3-8-alquilo C1-4, heteroaril C5-10-alquilo C1-4, espiro, heterocicloalquilo C3-8 y heterocicloalquil C3-8-alquilo C1-4, Rb hidrogeno o un radical eventualmente sustituido seleccionado del grupo compuesto por aIquilo C1-8, cicloalquilo C3-8, alquenilo C2-8, cicloalquenilo C3-8, haloalquilo C1-6, arilo C6-14, aril C6-14-alquilo C1- 5, heteroarilo C5-10, cicloalquil C3-8-alquilo C1-4, cicloalquenil C3-8-alquilo C1-4, heteroaril C5-10-alquilo C1-4, espiro, heterocicloalquilo C3-8, CONH2, aril C6-14-NH- y heterocicloalquil C3-8-NH-; R1 hidrogeno o un radical eventualmente sustituido seleccionado del grupo compuesto por alquilo C1-8, cicloalquilo C3-8, alquenilo C2-8, alquinilo C2-8 y aril C6-14-alquilo C1-5; R2 hidrogeno o un radical eventualmente sustituido seleccionado del grupo compuesto por alquilo C1-8, cicloalquilo C3-8, alquenilo C2-8, cicloalquenilo C3-8, haloalquilo C1-6, arilo C6-14, aril C6-14-alquilo C1-5, heteroarilo C5-10, cicloalquil C3-8-alquilo C1-4, cicloalquenil C3-8-alquilo C1-4, heteroaril C5-10-alquilo C1-6, espiro C9-13, heterocicloalquilo C3-8, heterocicloalquil C3-8-alquilo C1-6 y aril C6-14-alquilo C1-6 o R1 y R2 forman juntos un anillo eventualmente sustituido de cinco, seis o siete miembros compuesto por átomos de carbono y eventualmente 1 a 2 heteroátomos, seleccionados del grupo compuesto por oxigeno, azufre y nitrogeno o R1 y R2 forman juntos un anillo espirocíclico de 9 a 13 miembros eventualmente sustituido, o R2 un radical seleccionado del grupo compuesto por las formulas generales (A1) a (A18), en donde significan X e Y pueden estar unidos con el mismo o con distintos átomos de G, y X un enlace o un radical eventualmente sustituido seleccionado del grupo compuesto por alquileno C1-7, alquenileno C3-7 y alquinileno C3-7, o X forma junto con R1, R3 o R4 un puente de alquileno C1-7, Y un enlace o eventualmente sustituido alquileno C1-4, Q un radical eventualmente sustituido seleccionado del grupo compuesto por alquileno C1-7, alquenileno C3-7 y alquinileno C3-7, o Q forma junto con R1, R3 o R4 un puente de alquileno C1-7, R3, R4, R5 iguales o diferentes, hidrogeno o un radical eventualmente sustituido seleccionado del grupo compuesto por alquilo C1-8, cicloalquilo C3-8, haloalquilo C2-6, alquil C1-4-cicloalquilo C3-8, cicloalquil C3-8-alquilo C1-4, NR7R8, NR7R8-alquilo C1-4-, alcoxi C1-4, alcoxi C1-4-alquilo C1-4, arilo C6-14 y heteroarilo C5-10, o dos de los sustituyentes R3, R4, R5 forman juntos un anillo eventualmente sustituido de cinco, seis o siete miembros, compuesto por átomos de carbono y eventualmente 1-2 heteroátomos, seleccionados del grupo compuesto por oxigeno, azufre y nitrogeno; G un sistema de anillos saturado, parcialmente saturado o insaturado de 3-10 átomos de C, en donde eventualmente hasta 6 átomos de C están reemplazados por heteroátomos seleccionados del grupo compuesto por nitrogeno, oxígeno y azufre; R6 igual o diferente, hidrogeno o un radical eventualmente sustituido, seleccionado del grupo compuesto por =O, alquilo C1-8, cicloalquilo C3-8, haloalquilo C2-8, arilo C6-14, heteroarilo C5-10, heterocicloalquilo C3-8, o un radical seleccionado del grupo compuesto por NR7R8, OR7, -CO-alquil C1-3-NR7R8, -O-alquil C1-3-NR7R8, CONR7R8, NR7COR8, -CO-alquil C1-3-NR7(CO)OR8, - O(CO)NR7R8, NR7(CO)NR8R9, NR7(CO)OR8, (CO)OR7, -O(CO)R7, COR7, (SO)R7, (SO2)R7, (SO2)NR7R8, NR7(SO2)R8, NR7(SO2)NR8R9, CN y halogeno; n 1, 2 o 3; R7, R8, R9 iguales o diferentes, hidrogeno o un radical eventualmente sustituido seleccionado del grupo compuesto por alquilo C1-8, cicloalquilo C3-8, haloalquilo C1-6, alquil C1-4-cicloalquilo C3-8, cicloalquil C3-8-alquilo C1-3, arilo C6-14, alquil C1-4-arilo C6-14, aril C6-14-alquilo C1-4, heterocicloalquilo C3-8, alquil C1-5-heterocicloalquilo C3- 8, heterocicloalquil C3-8-alquilo C1-4, alquil C1-4(CO)- y alquil C1-4-O(CO)-; o dos de los sustituyentes R7, R8, R9 forman juntos un anillo eventualmente sustituido de cinco seis o siete miembros, compuesto por átomos de carbono y eventualmente 1-2 heteroátomos, seleccionados del grupo compuesto por oxigeno, azufre y nitrogeno; eventualmente en forma de sus tautomeros, sus racematos, sus enantiomeros, sus diastereoisomeros y sus mezclas, así como eventualmente sus sales por adicion de ácidos, solvatos e hidratos farmacologicamente inocuos, con la condicion de que se excluyan los siguientes compuestos: a) (1-fenil-4,5-dihidro-1H-pirazolo[3',4':3,4]benzo[1,2-d]tiazol-7-iI)-hidrazincarboxamida, b) 1-(2-dimetilamino-etil)-3-(1-fenil-4,5- dihidro-1H-pirazolo[3',4':3,4]benzo[1,2-d]tiazol-7-il)-urea, c) 1-(2-morfolin-4-il-etil)-3-(1-fenil-4,5-dihidro-1H-pirazolo[3',4':3,4]benzo[1,2-d]tiazol-7-il)-urea, d) 1-etil-3-(1-fenil-4,5-dihidro-1H-pirazolo[3',4':3,4]benzo[1,2-d]tiazol-7-iI)- urea, e) 1-metil-3-(1-fenil-4,5-dihidro-1H-pirazolo[3',4':3,4]benzo[1,2-d]tiazol-7-il)-urea, f) 1,1-dimetil-3-(1-fenil-4,5-dihidro-1H-pirazolo[3',4':3,4]benzo[1,2-d]tiazol-7-il)-urea, g) (1-fenil-4,5-dihidro-1H-pirazolo[3',4':3,4]benzo[1,2-d]tiazol- 7-iI)-amida del ácido morfolin-4-carboxílico, h) [1-(2-cloro-fenil)-3-isopropil-4,5-dihidro-1H-pirazolo[3',4:3,4]benzo[1,2-d]tiazol-7-il]-urea, i) N-(5,8-dihidro-4H-[1,3tiazolo[4,5-g]indol-2-il)-N'-etilurea, j) N-etil-N'-(8-metil-5,8-dihidro-4H- [1,3]tiazolo[4,5-g]indol-2-il)urea, k) éster terc butílico del ácido {4-[3-(1-fenil-4,5-dihidro-1H-pirazolo(3'4':3,4]benzo[1,2-d]tiazol-7-il)-ureido]-but-2-inil}-carbámico, l) 1-(4-amino-but-2-inil)-3-(1-fenil-4,5-dihidro-1H- pirazolo[3',4':3,4]benzo[1,2-d]tiazol-7-il)-urea, m) (1-fenil-4,5-dihidro-1H-pirazolo[3',4':3,4]benzo[1,2-d]tiazol-7-il)-urea.
ARP070101386A 2006-04-06 2007-04-03 Tiazolil - dihidro - indazoles AR060268A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06112299 2006-04-06

Publications (1)

Publication Number Publication Date
AR060268A1 true AR060268A1 (es) 2008-06-04

Family

ID=36778288

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101386A AR060268A1 (es) 2006-04-06 2007-04-03 Tiazolil - dihidro - indazoles

Country Status (15)

Country Link
US (1) US20070259855A1 (es)
EP (1) EP2018386A1 (es)
JP (1) JP2009532414A (es)
KR (1) KR20090006181A (es)
CN (1) CN101460507A (es)
AR (1) AR060268A1 (es)
AU (1) AU2007236044A1 (es)
BR (1) BRPI0710847A2 (es)
CA (1) CA2647434A1 (es)
IL (1) IL194492A0 (es)
MX (1) MX2008012332A (es)
RU (1) RU2008143552A (es)
TW (1) TW200806676A (es)
WO (1) WO2007115930A1 (es)
ZA (1) ZA200807580B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007004051A (es) * 2004-10-07 2007-05-24 Boehringer Ingelheim Int Pi3-quinasas.
US20070238746A1 (en) * 2006-04-06 2007-10-11 Trixi Brandl Thiazolyl-dihydro-chinazoline
US7691868B2 (en) 2006-04-06 2010-04-06 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-quinazoline
WO2008001883A1 (fr) * 2006-06-29 2008-01-03 Nissan Chemical Industries, Ltd. DÉRIVÉ D'ACIDE α-AMINÉ ET PRODUIT PHARMACEUTIQUE QUI LE COMPREND EN TANT QUE MATIÈRE ACTIVE
US20090325956A1 (en) * 2006-10-13 2009-12-31 Takahiko Taniguchi Aromatic amine derivative and use thereof
UY31700A (es) * 2008-03-13 2009-11-10 Boehringer Ingelheim Int Tiazolil-dihidro-indazoles
AU2009286604B2 (en) * 2008-08-29 2015-05-28 Onxeo Dk, Branch Of Onxeo S.A., France Novel urea and thiourea derivatives
EP2327704A4 (en) * 2008-08-29 2012-05-09 Shionogi & Co RING-CONDENSED AZOL DERIVATIVE WITH PI3K-INHIBITING EFFECT
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
US8293753B2 (en) * 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
US8980878B2 (en) * 2012-04-17 2015-03-17 Gilead Sciences, Inc. Compounds and methods for antiviral treatment
US11633399B2 (en) 2018-12-25 2023-04-25 Sol-Gel Technologies Ltd. Treatment of skin disorders with compositions comprising an EGFR inhibitor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5547975A (en) * 1994-09-20 1996-08-20 Talley; John J. Benzopyranopyrazolyl derivatives for the treatment of inflammation
KR20020084116A (ko) * 2000-02-07 2002-11-04 애보트 게엠베하 운트 콤파니 카게 2-벤조티아졸릴 우레아 유도체 및 이의 단백질 키나제억제제로서의 용도
DE10344223A1 (de) * 2003-09-24 2005-04-21 Merck Patent Gmbh 1,3-Benzoxazolylderivate als Kinase-Inhibitoren
MX2007004051A (es) * 2004-10-07 2007-05-24 Boehringer Ingelheim Int Pi3-quinasas.
UY29149A1 (es) * 2004-10-07 2006-05-31 Boehringer Ingelheim Int Tiazolil-dihidro-indazoles
EP2007774B1 (de) * 2006-04-06 2012-07-25 Boehringer Ingelheim International GmbH Thiazolyldihydroindazol-derivate als proteinkinase- inhibitoren
US20070238746A1 (en) * 2006-04-06 2007-10-11 Trixi Brandl Thiazolyl-dihydro-chinazoline
US7691868B2 (en) * 2006-04-06 2010-04-06 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-quinazoline
JP2009532425A (ja) * 2006-04-06 2009-09-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング チアゾリルジヒドロインダゾール
US7517995B2 (en) * 2006-04-06 2009-04-14 Boehringer Ingelheim International Gmbh Thiazolyl-dihydro-cyclopentapyrazole
US20070238718A1 (en) * 2006-04-06 2007-10-11 Matthias Grauert Thiazolyl-dihydro-indazole

Also Published As

Publication number Publication date
TW200806676A (en) 2008-02-01
AU2007236044A1 (en) 2007-10-18
JP2009532414A (ja) 2009-09-10
BRPI0710847A2 (pt) 2011-08-23
CN101460507A (zh) 2009-06-17
MX2008012332A (es) 2008-10-09
IL194492A0 (en) 2009-08-03
US20070259855A1 (en) 2007-11-08
CA2647434A1 (en) 2007-10-18
EP2018386A1 (de) 2009-01-28
WO2007115930A1 (de) 2007-10-18
RU2008143552A (ru) 2010-05-20
ZA200807580B (en) 2009-07-29
KR20090006181A (ko) 2009-01-14

Similar Documents

Publication Publication Date Title
AR060268A1 (es) Tiazolil - dihidro - indazoles
AR060267A1 (es) Tiazolil- dihidro -ciclopentapirazoles
AR060265A1 (es) Tiazolil - dihidro -quinazolinas
AR054963A1 (es) Inhibidores de girasas y usos de los mismos
AR054529A1 (es) Derivados de benzazepina como moduladores del receptor de 5-hidroxi-triptamina 6
AR119698A2 (es) Compuesto amida n-urea sustituida derivado de aminoácido
AR041941A1 (es) Derivado de 1-aminociclohexano sustituidos en la posicion 4 utilizado como receptor orl1
AR040332A1 (es) Derivados de acido benzoico como moduladores de ppar alfa y gamma
AR050194A1 (es) Analogos de biaril piperazinil-piridina sustituidos
AR059687A1 (es) Derivados de pirazol inhibidores de la enzima mao-b,utiles para mejorar la funcion cognitiva, composiciones farmaceuticas que los contienen,y metodo de preparacion.
AR048974A1 (es) Derivados sustituidos del dioxido de oxazol-benzoisotiazol y composiciones farmaceuticas.
AR040409A1 (es) Inhibidores de histona desacetilasa
CO5640152A2 (es) Composiciones farmaceuticas para inhibidores de la proteasa del virus de la hepatitis c
AR041250A1 (es) Derivados de sulfonamida como inhibidores de enzimas convertidoras de tnf-alfa
AR025386A1 (es) Moduladores de los receptores activados del proliferador de peroxisomas
AR044614A1 (es) Composiciones de sulfonamida que modulan la actividad del receptor de quinioquinas (ccr4)
AR038341A1 (es) Compuestos que son agonistas de receptores alfa-1 preferentemente agonistas de receptores alfa-1a/l
AR063311A1 (es) Compuestos organicos
ECSP088431A (es) Derivados de pirazolo
AR070274A1 (es) Derivados arilamida diazepinopirimidona sustituidos utiles en el tratamiento y/o prevencion de enfermedades neurodegenerativas y otras, provocadas por la actividad anormal de quinasas gsk3beta, medicamentos que los contienen y proceso de preparacion e intermediarios.
AR035417A1 (es) Derivados triciclicos de lactama y sultama, procesos para su elaboracion, medicamentos que los contienen, y el uso de dichos compuestos en la preparacion de medicamentos
AR039226A2 (es) Compuestos utiles como intermediarios de preparacion y procedimientos
AR061835A1 (es) Derivados tetraciclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
CO5690582A2 (es) Derivados de n-tiazol-2-il-benzamida
AR055698A1 (es) Tiazolidinonas metasustituidas, su preparacion y su uso como medicamento

Legal Events

Date Code Title Description
FA Abandonment or withdrawal
FB Suspension of granting procedure